Home   Business   Article

Subscribe Now

OKRA.ai to expand collaboration in EU with pharma company Bristol Myers Squibb

More news, no ads


OKRA.ai is extending its collaboration with pharmaceutical company Bristol Myers Squibb.

The partnership began in the UK in 2018 and involved OKRA’s AI technology being used to bring together multiple data sources, generate intelligent insights for commercial teams and drive automation at the New York-headquartered pharma.

Loubna Bouarfa, CEO & Founder OKRA. Picture: Keith Heppell. (21835209)
Loubna Bouarfa, CEO & Founder OKRA. Picture: Keith Heppell. (21835209)

The companies expanded their partnership into new markets last year and are set to extend it further in the European Union this year, with a focus on supporting customer engagement.

Loubna Bouarfa, CEO of OKRA.ai and a former winner of CEO of the Year at the Cambridge Independent Science and Technology Awards, said: “We’re very excited to announce the work with Bristol Myers Squibb. We started in 2018 and have been continuously validating the benefit and accuracy of our insights with the team.

“This journey has seen us deploy a fully automated portal that uses vast amounts of data and not rules to support dynamic decision making across the commercial organisation.

“We continue to educate the industry on what it means to truly have an AI brain where automation, data pipelines, accuracy, explainability and transparency are fundamental to success and Bristol Myers Squibb have fully embraced this with us.”

OKRA applies AI to all stages of the drug life cycle, covering market access, medical and commercial fields.

Read more

OKRA.ai to collaborate with AWS for Health initiative

OKRA Technologies unveils ValueScope to predict new drug prices years before launch

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More